Serum IgA Fc effector functions in infectious disease and cancer.
Immunoglobulin A (IgA) is the most abundant antibody isotype present at mucosal surfaces and the second most abundant in human serum. In addition to preventing pathogen entry at mucosal surfaces, IgA can control and eradicate bacterial and viral infections through a variety of antibody-mediated innate effector cell mechanisms. The role of mucosal IgA in infection (e.g. neutralisation) and in inflammatory homeostasis (e.g. allergy and autoimmunity) has been extensively investigated, in contrast serum IgA is comparatively understudied. IgA binding to Fc alpha receptor plays a dual role in the activation and inhibition of innate effector cell functions. Mounting evidence suggests serum IgA induces potent effector functions against various bacterial and some viral infections including Neisseria meningitidis and rotavirus. Furthermore, in the era of immunotherapy, serum IgA provides an interesting alternative to classical IgG monoclonal antibodies to treat cancer and infectious pathogens. Here we discuss the role of serum IgA in infectious diseases with reference to bacterial and viral infections and the potential for IgA as a monoclonal antibody therapy.